Hanmi holds third symposium for Amosartan

Published: 2012-07-11 06:56:00

Updated: 2012-07-11 06:56:00

Hanmi Pharmaceutical Co. said that it has successfully completed its nationwide symposium for Amosartan, hypertension combination drug combination drug of amlodipine camsylate and losartan potassium, between May 22 and 26 to commemorate the drug’s third launching anniversary with around 1,100 Kor...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK